Save

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

PHASE1RECRUITING

This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).

Simpliy with AI

Study details:

This phase 1, single arm, single centre study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate in patients with metastatic NET. Patients will receive 1 cycle of 177Lu-DOTA-Octreotate alone followed by 3 cycles of 177Lu-DOTA-Octreotate combined with 5 days of talazoparib.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Patient must be > or equal to 18 years of age and must have provided written informed consent.

Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Histologically confirmed Grade 2 NET, Ki-67 of 3-20%, from pancreatic or intestinal origin.

Patient clinically suitable for PRRT

Tumor SSR uptake on GaTate PET/CT higher than liver activity, ≥ modified Krenning 3 score

No discordant FDG-avid disease on FDG PET/CT

No evidence of significant uncorrected carcinoid heart disease

Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled assessments

Patients must have adequate bone marrow, hepatic and renal function defined as: Haemoglobin ≥100 g/L, Absolute neutrophil count ≥1.5x109/L, Platelets ≥150 x109/L, Total bilirubin ≤1.5 x upper limit of normal (ULN), Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT) ≤2.5 x ULN if there is no evidence of liver metastasis or ≤5 x ULN in the presence of liver metastases, Albumin ≥ 30 g/L, Adequate renal function: eGFR ≥ 60 ml/min

Exclusion criteria

Surgery or radiotherapy within <3 weeks of registration. Patients must have recovered from any effects of any major surgery.

Any prior exposure to peptide receptor radionuclide therapy (177Lu, 111In or 90Y labelled), PARPi, immunotherapy

Uncontrolled intercurrent illness that is likely to impede participation and /or compliance

Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ.

Previous or current history of myelodysplastic syndrome/acute myeloid leukemia

Patients unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with the absorption of the study medication.

Use of strong P-gp inhibitors (eg, dronedarone, quinidine, ranolazine, verapamil, ketoconazole, itraconazole), P-gp inducers (eg, rifampin, tipranavir/ritonavir), or BCRP inhibitors (eg, elacridar [GF120918]) should be avoided.

Participation in another clinical study with an investigational product or another systemic therapy administered in the last 3 weeks (except short acting SSA).

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2021-12-08

Primary completion: 2029-06-30

Study completion finish: 2029-06-30

Study type

TREATMENT

Phase

PHASE1

Trial ID

NCT05053854

Intervention or treatment

DRUG: Talazoparib

Conditions

• Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
DRUG: Talazoparib
Melbourne, Victoria, Australia
Sponsor: Peter MacCallum Cancer Centre, Australia

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Peter MacCallum Cancer Centre

Research sites nearby

Select from list below to view details:

Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: 177Lu-DOTA-Octreotate + talazoparib Patients will receive 4 cycles of 177Lu-DOTA-Octreotate every 8 weeks, the last 3 cycles combined with talazoparib on days 2-6 of each cycle.	DRUG: Talazoparib During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Maximum tolerated dose Talazoparib with 177Lu-DOTA-Octreotate	Maximum tolerated dose of Talazoparib when given in combination with 177Lu-DOTA-Octreotate	Through study completion, up to 18 months following first administration of PRRT.
Dose limiting toxicity talazoparib	The toxicity (haematologic or non-haematologic) that prevents further administration of the trial talazoparib treatment at that dose level.	Each cohort of 3 patients be assessed for DLTs in the first 6 weeks (cycle 2) of treatment and a dose for the next cohort will be determined (each cycle is 8 weeks)

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Adverse Events and Serious Adverse Events measured using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	Safety of the combination will be measured by AEs and SAEs	Through Study completion, up to 18 months after the last patient commences treatment.
Radiographic progression free survival	The time from treatment initiation to the first date of progression on imaging or death due to any cause. Imaging progression will be assessed by RECIST 1.1. Patients who commence new systemic therapy before evidence of disease progression on conventional imaging will be considered to have progressed.	Through study completion, up to 18 months following first administration of PRRT.
Overall Survival	The time from treatment initiation to the date of death due to any cause. For patients alive, the time will be censored at the last time the patients was known to be alive.	Through study completion, up to 18 months following first administration of PRRT.
Treatment discontinuation due to toxicity	The number of patients who discontinue treatment at any time due to treatment related toxicity will be reported and will be also categorised by dose level.	Through study completion, up to 18 months following first administration of PRRT.
Rate of Treatment discontinuation due to toxicity	The percentage of patients who discontinue treatment due to treatment related toxicity will be reported and will be also categorised by dose level	Through study completion, up to 18 months following first administration of PRRT.

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours